Introduction
============

Antimicrobial resistance (AMR) is emerging as a global health security threat.[@b1-idr-8-379],[@b2-idr-8-379] The World Health Organization's Global Action Plan against AMR identified surveillance as one of the key pillars to combat this menace.[@b3-idr-8-379] In resource-rich settings, extensive national and regional programs have been developed to monitor AMR patterns over time.[@b4-idr-8-379] Examples include the Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance,[@b5-idr-8-379] the European AMR Surveillance System,[@b6-idr-8-379] and the Antimicrobial Resistance Monitoring and Research programme.[@b7-idr-8-379] In contrast, the infrastructure and resources needed to implement such surveillance systems in resource-limited settings (RLS) are unavailable.[@b4-idr-8-379] Many RLS, including Ghana, have a high burden of infectious diseases that require antimicrobial therapy to save lives.[@b8-idr-8-379] In addition to the lack of infrastructure to investigate these infectious diseases in RLS, spurious, falsified, and counterfeit drugs often slip into the drug supply chain.[@b9-idr-8-379] These highlight the importance of AMR surveillance, especially in RLS. Such systems will feed into larger global platforms of AMR monitoring.

An AMR Working Group has been instituted in Ghana to create a policy platform, develop policy framework and implementation plan, and to help raise awareness on the menace of AMR.[@b10-idr-8-379] The Director of Pharmacy at the Ministry of Health (MOH) chairs this working group. Members include key stakeholders in health care, regulatory authorities, academia, research institutions, veterinary clinics, civil society organizations, and others. In addition, the MOH, in collaboration with local and international organizations, has developed Ghana's Essential Medicines List and National Drug Policy.[@b11-idr-8-379] The first ever African Conference on Antibiotic Use and Resistance was also held in Ghana between March 18 and 20, 2015, to disseminate research information on AMR.[@b12-idr-8-379]

Laboratory-based surveillance is required for local and national action in the monitoring of AMR and its spread.[@b13-idr-8-379],[@b14-idr-8-379] Individual scientists and researchers have been working on AMR in Ghana. However, their research findings are usually not well coordinated and they target either specific pathogens or infections.[@b15-idr-8-379]--[@b18-idr-8-379] Between 2002 and 2003, Newman et al conducted the first ever surveillance of AMR in Ghana.[@b19-idr-8-379] Though data generated from this surveillance have been useful over the years, up-to-date information is needed to inform and direct policy issues in Ghana. The aim of the current study is to generate baseline data on AMR and to identify potential gaps that may affect future collaboration and data sharing in local and national surveillance efforts.

Methods
=======

Laboratory selection and training workshop
------------------------------------------

Study laboratories were selected based on the recommendations from the AMR Working Group, Ghana.[@b15-idr-8-379] The categories of the laboratories included are as follows: three teaching hospitals -- Korle-Bu (AcK), Komfo Anokye (AsK), and Tamale (NoT); seven regional hospitals -- Ridge (AcR), Eastern (EaK), Central (CeT), Volta (VoV), Brong Ahafo (BaS), Upper East (UeB), and Upper West (UwR); three zonal public health reference laboratories (PHRLs) -- National Public Health Reference Laboratory (NPHRL) (AcP), Kumasi (AsP), and Sekondi (WsE); four faith-based hospitals -- St Patrick's Holy Family Berekum (BaB), St Patrick's Holy Family Nkawkaw (EaN), St Patrick, Offinso (AsO), and Presbyterian Hospital, Agogo (AsA); three district hospitals -- LEKMA (AcL), Tema (AcT), and Tetteh Quarshie (EaT); two research laboratories -- Kintampo (BaK) and War Memorial (UeW); and two quasi-government hospitals -- 37 Military (Ac3) and Cape Coast University Hospital (CeU).

The AMR surveillance study spanned 6 months, from June to November 2014. Before commencement, a 3-day residential workshop was organized to harmonize susceptibility testing protocols. Issues related to logistics for the surveillance were also addressed. Geographically, Ghana was divided into two sectors (southern and northern) for the training workshop. The trainings were done 2 weeks apart at the University of Ghana Medical School, and the Kwame Nkrumah University of Science and Technology, for the southern and northern sectors, respectively. In total, 33 technologists from 24 laboratories participated in the two workshops. Training included classroom lectures, and practical sessions using the Clinical Laboratory Standard Institute[@b20-idr-8-379] guidelines for susceptibility testing. A predesigned data collection sheet was thoroughly discussed and adapted ([Figure S1](#SD1-idr-8-379){ref-type="supplementary-material"}). The data collection sheet sought to capture basic information on patients, specimen types, bacteria isolated, antimicrobial agents tested and inhibitory zone sizes, as well as initials of the technologists submitting data. Study laboratories were requested to submit data on multidrug-resistant (MDR) isolates from all specimen types. Multidrug resistance was defined as resistance to two or more antibiotic classes.[@b20-idr-8-379]

Antimicrobial susceptibility testing
------------------------------------

Study laboratories performed routine microbiological investigations on all clinical specimens received using in-house standard operating procedures. Bacterial isolates were identified as far as possible using Gram morphology, routine biochemical tests, and in some instances the API 20E system (bioMérieux SA, Marcy l'Etoile, France). Susceptibility tests were performed by the disk diffusion method,[@b21-idr-8-379] and inhibition zones sizes were measured and reported in millimeters. Gram-negative and gram-positive antimicrobial disks were selected for gram-negative and gram-positive isolates, respectively. The disks tested and their concentrations in micrograms included: ampicillin (10), piperacillin (100), amoxicillin/clavulanic acid (20/10), cefuroxime (30), cefotaxime (30), meropenem (10), imipenem (10), amikacin (30), gentamicin (15), nalidixic acid (30), ciprofloxacin (5), ofloxacin (5), trimethoprim/sulfamethoxazole (1.25/23.75), erythromycin (15), nitrofurantoin (300), chloramphenicol (30), tetracycline (30), flucloxacillin, oxacillin (1), and cefoxitin (30). Pure isolates were stabbed on Mueller--Hinton agar slants and labeled appropriately using pathological codes of patients. Biomedical scientists additionally completed a surveillance data collection sheet ([S1](#SD1-idr-8-379){ref-type="supplementary-material"}). Approximately a quarter of the study laboratories routinely participate in External Quality Assurance Systems.

Surveillance data and isolate submission
----------------------------------------

Biweekly, biomedical scientists sent completed data sheets together with bacterial isolates in cold boxes to the Medical Microbiology Department, School of Biomedical and Allied Health Sciences (MD-SBAHS). In-country courier systems were mostly used in the transportation of materials between the study laboratories and MD-SBAHS. A research assistant was employed for liaising with the study laboratories. The research assistant worked under the direct supervision of the research team. He was scheduled to conduct random quality checks, and additional tests, including minimum inhibitory concentration (MIC) and extended-spectrum beta-lactamase (ESBL) tests. Finally, he entered all data received into WHO-NET database files.[@b22-idr-8-379]

Further microbiological tests
-----------------------------

*Klebsiella* spp. and *Escherichia coli* isolates, found to be resistant to third-generation cephalosporins, were tested to detect the presence of ESBLs, using methods described elsewhere,[@b23-idr-8-379] and interpreted using the Clinical Laboratory Standards Institute guidelines.[@b20-idr-8-379] Cefotaxime--clavulanate combination versus cefotaxime or ceftazidime--clavulanate combination versus ceftazidime disk were used (MAST, Germany). ESBL-positive isolates were additionally tested to determine their susceptibility to meropenem by the disk diffusion method.[@b21-idr-8-379] MIC tests were carried out on randomly selected MDR isolates using E-test strips (bioMérieux SA, France). Antimicrobials tested included ceftriaxone, ciprofloxacin, and amikacin. The manufacturer's instructions and recommendations were used to interpret results. *E. coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923 were included as control strains for susceptibility tests.

Data management and analysis
----------------------------

All surveillance data and isolates were cataloged and kept at MD-SBAHS. Soft copies of data were stored in the WHONET program file, which was also used to generate antibiogram profiles.[@b22-idr-8-379] For the purposes of analyses, the geographical border of Ghana was divided into southern, middle, and northern sectors ([Figure 1](#f1-idr-8-379){ref-type="fig"}). Data were summarized in tables and graphs. Chi-square test was used to analyze associations between the different sectors, after data was exported into Epi Info.[@b24-idr-8-379] Statistical significance was determined at *P*-value \<0.05. Intermediate resistance of susceptibility test was considered resistant.

Ethical consideration
---------------------

The MOH in conjunction with the Ghana Health Services (Institutional Care Division) granted permission to carry out the study. Additional permission was also sought from the medical directors of the respective health facilities where laboratories were located. To maintain confidentiality, patient information was codified. As this was a laboratory surveillance only, patient consent was not necessary.

Results
=======

Participating laboratories and data received
--------------------------------------------

[Figure 1](#f1-idr-8-379){ref-type="fig"} shows all ten regional boundaries of Ghana with the exact geographical locations of the study laboratories. With the exception of the Upper West Region that did not submit any data, we received and analyzed data from the other nine regions of Ghana. A total of 1,606 data sets were received from 18 of 24 (75%) study laboratories. Out of this total, 1,598 data sets were included in the final analysis. The rest (eight) were excluded during data cleaning. Total data sets received from the southern, middle, and northern sectors were 1,069, 417, and 112, respectively. Six of the 24 laboratories did not submit any data within the surveillance period. Data received from teaching hospitals, PHRLs, and a district hospital were as follows: AcK 699 (43.7%), NoT 102 (6.4%), AsK 7 (0.4%); WsE 152 (9.5%), AcP 0 (0%); and AcL 110 (6.9%), respectively. Out of the three PHRLs that participated in the current surveillance, only one submitted data.

Bacteria species isolated
-------------------------

Bacterial species isolated included *S. aureus* (183), coagulase-negative *Staphylococcus* (45), *Streptococcus* spp. (37), *Salmonella enterica* serovar Typhi (9), nontyphoidal *Salmonella* (7), *E. coli* (440), *Klebsiella* spp. (114), *Pseudomonas aeruginosa* (118), *Citrobacter* spp. (163), and *Vibrio cholerae* (54) ([Table 1](#t1-idr-8-379){ref-type="table"}). Bacteria were isolated from inpatients (428; 26.8%) and outpatients (963; 60.3%). The sources for the remaining isolates were not indicated (161; 10.1%). Specimen types that grew the bacterial isolates were diverse and varied. They included blood, urine, stool, swabs (ear, eye, wound, etc), and sputum ([Table 2](#t2-idr-8-379){ref-type="table"}). In 2.8% (46/1,598) of the data sets, the specimen type was not indicated. More females (839; 53%) than males (660; 41%) were involved in the study; the sex data of the remaining patients were missing (99; 6%). The age distributions of the patients in years were as follows: \<1,113 (7.1%); 1--40, 373 (23.3%); 41--60, 234 (14.6%); \>61, 246 (15.4%). The ages of the rest were not indicated (396; 24.8%).

[Table 2](#t2-idr-8-379){ref-type="table"} shows that though most of the laboratories have capacity for urine culture, many lacked capacity for blood culture. The highest number of blood culture specimens (45) was received from the Sunyani Regional Hospital, and none from the Korle-Bu Teaching Hospital.

Resistance profiles
-------------------

[Figure 2](#f2-idr-8-379){ref-type="fig"} summarizes resistance profiles of gram-negative and gram-positive isolates that were tested against important antimicrobials. For both gram-negative and gram-positive isolates, the majority of the antimicrobial agents tested were ineffective, across the southern, middle, and northern sectors of Ghana. The WHONET expert rule indicated that over 50% of the gram-negative isolates from the southern and middle sectors were beta-lactamase-producing bacteria ([Figure 2A](#f2-idr-8-379){ref-type="fig"}). Additionally, nearly 90% of the gram-negative isolates were ESBL-producing ([Figure 2A](#f2-idr-8-379){ref-type="fig"}). Older drugs such as ampicillin, tetracycline, chloramphenicol, and trimethoprim sulfamethoxazole were ineffective (80%) against the isolates tested. However, the isolates showed resistance levels of \<50% for injectables such as amikacin and gentamicin. Especially for gram-negative isolates, resistance profiles for the third-generation cephalosporins and quinolones such as nalidixic acid and ciprofloxacin were high -- \>50% across all the sectors of the country. For gram-positive isolates, cefoxitin resistance was \<50% in the northern and southern sectors, but almost 100% for the middle sector ([Figure 2B](#f2-idr-8-379){ref-type="fig"}). Resistance profile for piperacillin was very high in the northern and middle sectors (\~80% and 70%, respectively) compared to approximately 15% in the southern sector. Similarly, the nitrofurantoin resistance profile for the northern sector was high (\~70%), compared to the middle and southern sectors (\~30% and 40% respectively). Most of the gram-negative isolates were susceptible to meropenem across the country.

For several of the isolates tested, those from the northern sector had resistance profiles generally higher compared to that from the other sectors of the country. Especially for ciprofloxacin and penicillin, the differences observed in the resistance profiles between the southern and northern sectors were statistically significant (*P*\<0.05; [Figure 3](#f3-idr-8-379){ref-type="fig"}).

Phenotypic ESBL screening results
---------------------------------

Seventy-four percent (86/117) of enterobacteria (*E. coli*, n=81 and *Klebsiella* spp., n=5) were observed to be ESBL-producing isolates. These positive ESBL-producing *E. coli* and *Klebsiella* spp. had percentage resistance ranges \>85% to penicillins and third-generation cephalosporins (data not shown). As expected, these isolates were generally susceptible to cephamycins (cefoxitin) and carbapenemase (meropenem and imipenem).

MIC results
-----------

[Table 3](#t3-idr-8-379){ref-type="table"} shows the MIC~50~ and MIC~90~ results of randomly selected isolates that were MDR. MIC levels for gram-negative bacteria such as *E. coli*, *Enterobacter* spp., and *Pseudomonas* spp. were high (\>256 µg/mL; [Table 3](#t3-idr-8-379){ref-type="table"}). MIC~50~ and MIC~90~ of *Pseudomonas* spp. and *Klebsiella* spp. to ceftriaxone were \<4 µg/mL and \>256 µg/mL, respectively. In general, *Pseudomonas* had lower MIC~50~ and MIC~90~ to injectable antimicrobials such as amikacin ([Table 3](#t3-idr-8-379){ref-type="table"}).

Discussion
==========

Clinical specimen, isolates, and antibiogram
--------------------------------------------

Clinical specimens submitted for culture were diverse in the current study. Urine, swabs, (especially wound) and blood formed \>90% of all clinical specimens received by the study laboratories. Though this observation is consistent with studies conducted elsewhere,[@b4-idr-8-379],[@b7-idr-8-379] majority of the study laboratories did not perform blood cultures. For example, AcK, the largest tertiary referral hospital in Ghana, with over 2,500-bed capacity, did not process any blood culture during the surveillance period. Blood stream infections can be fatal.[@b25-idr-8-379] Apart from a few exceptions, including BaS (Regional), NoT (Teaching), WsE (PHRL), and AcL (District), the other study laboratories did not process enough blood cultures. This emphasizes the importance of surveillance in terms of promptly identifying possible gaps and taking necessary action in a timely and consistent manner to fix them.[@b4-idr-8-379]

Both gram-positive and gram-negative bacteria were identified in the current study, as is typical with studies conducted elsewhere.[@b4-idr-8-379],[@b7-idr-8-379] In the last decade, there had been a divided opinion on whether to target specific pathogens or whether to consider specific clinical syndromes in AMR surveillance.[@b3-idr-8-379] The current opinion, however, is to include priority infections such as bloodstream, urinary tract, diarrhea, and gonorrhea infections.[@b2-idr-8-379],[@b14-idr-8-379] In the present study, we considered all clinical specimens submitted for culture at the study laboratories, and, therefore, captured both clinical syndromes as well as pathogens associated with those conditions. Gram-negative pathogens top the list of bacteria identified in the current surveillance. This finding is similar to both short- and long-duration surveillance conducted elsewhere.[@b19-idr-8-379],[@b26-idr-8-379]--[@b28-idr-8-379] The few *Vibrio cholerae* isolates identified in the current study were from the last phases of the worst cholera outbreak that hit Ghana starting in January 2014 and lasting several months.[@b29-idr-8-379] Laboratories in Ghana lack capacity for anaerobic culture. Surveillance systems in well-endowed countries have cultured both aerobes and anaerobes.[@b30-idr-8-379],[@b31-idr-8-379]

Across the southern, middle, and northern sectors of Ghana, both gram-negative and gram-positive isolates showed varied levels of susceptibilities to the antimicrobials tested. Commonly used antimicrobials such as ampicillin, tetracycline, chloramphenicol, and trimethoprim--sulfamethoxazole were ineffective (\>70%) against gram-negative and gram-positive isolates. This is consistent with the studies conducted in Nigeria,[@b32-idr-8-379] Uganda,[@b33-idr-8-379] and Tanzania.[@b34-idr-8-379] These older antimicrobials are cheap, and their continued use (whether appropriate/inappropriate) in both humans and animals contribute to the high resistance levels.

In the present study, high prevalence levels (\>50%) of resistance were also observed in third-generation cephalosporins, and fluoroquinolones. Syndromic infections are often treated with third-generation cephalosporins, and high levels of resistance to these antimicrobials are worrisome.[@b35-idr-8-379],[@b36-idr-8-379] MDR ESBL-producing bacteria were found to be generally resistant to ampicillin, third-generation cephalosporins, and fluoroquinolones. Several studies conducted in Ghana[@b16-idr-8-379],[@b37-idr-8-379] and elsewhere have reported this phenomenon.[@b38-idr-8-379]

For treatment of urinary tract and blood stream infections, the Standard Treatment Guidelines, Ghana,[@b39-idr-8-379] recommends the use of ciprofloxacin. The high levels of ciprofloxacin resistance observed in the current study shows that we are gradually losing available treatment options. Globally, fluoroquinolones have been indiscriminately used for treating human infections[@b40-idr-8-379] and for controlling infections in farm animals.[@b40-idr-8-379] Most of the organisms studied in the current study had lower MIC levels, especially for ciprofloxacin. In an earlier study conducted in Ghana, MIC levels for ciprofloxacin were in the ranges of 0.004--32 µg/mL.[@b19-idr-8-379] MIC levels for ciprofloxacin in the current study ranged from 0.019 to \>256 µg/mL. The seeming rise in resistance levels of ciprofloxacin over time in Ghana raises concerns about the need for action.

Preparedness of Ghana in local and national AMR surveillance
------------------------------------------------------------

In the current laboratory-based surveillance of AMR, data sets were received and processed from \>70% of the 24 laboratories that participated in the training workshop. However, six laboratories did not submit any data during the surveillance period. Our preliminary investigations revealed some lapses within these hospitals, including breakdown of culture facilities, clinicians not making request for culture, and some internal managerial issues. More than two-thirds of the data analyzed in the current surveillance were from the southern sector, with less than one-tenth from the northern sector. In 2003, a similar nationwide surveillance of AMR also received a relatively small number of isolates from the northern parts of Ghana.[@b19-idr-8-379] Such disparities may introduce some biases while interpreting the results to direct antibiotic policy in Ghana. Considerations such as the general lack of access to health care facilities in remote and rural parts in the northern parts of Ghana, economic and social reasons, and patronage of traditional medications (herbs) compared to orthodox medicine have to be factored into interpretation of surveillance data.[@b41-idr-8-379] The Korle-Bu Teaching Hospital alone submitted \>50% of the total data sets. Generally, academic tertiary referral laboratories are known to be over-represented in national and multicenter surveillance systems.[@b42-idr-8-379] This overrepresentation of data introduces some biases in the overall AMR surveillance results. The Komfo Anokye Teaching Hospital did not submit enough data in the current surveillance compared to their output in the previous study.[@b19-idr-8-379]

Ghana has four PHRLs, one each in Greater Accra, Ashanti, Brong Ahafo, and the northern regions. The Greater Accra PHRL doubles up as the NPHRL. Reference laboratories participated in the current surveillance but data were received from only one, Brong Ahafo. Some proposals have suggested that AMR surveillance systems should be coordinated by PHRLs.[@b43-idr-8-379] In the case of Ghana, perhaps PHRLs are not yet ready to spearhead AMR surveillance activities. The mandate, direction, and functions of PHRLs in Ghana must be critically aligned to address the global public health threat of AMR. Grundmann et al suggested that global AMR surveillance systems must have separate functions including reference work, quality assessment, and the actual surveillance.[@b43-idr-8-379] In Ghana, the NPHRL may play a vital role in future laboratory-based surveillance, by participating in quality assessments. In the present study, faith-based and district hospitals also submitted data. Since these hospitals contribute greatly to the health needs of Ghana, they should be included in future national AMR surveillance programs. In general, the current study did not observe disparities in susceptibility results compared to the results of the previous study in Ghana.[@b19-idr-8-379]

Conclusion
==========

This laboratory-based surveillance shows that important antimicrobial agents used in the country are not as highly effective against a range of clinical isolates as was previously believed. The study also highlights the need for con tinuous surveillance of AMR for local and national action. Additionally, the capacity and infrastructure for culture and susceptibility testing across Ghana needs improvement, especially in facilities in the northern parts of the country.
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======================
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![Ten regional boundaries of Ghana showing study laboratories.\
**Notes:** Regional hospitals: AcR -- Ridge (25), EaK -- Eastern (142), VoV -- Volta (56), BaS -- Brong Ahafo (209), UwR -- Upper West (0), UeB -- Upper East (0)\*. District hospitals: AcT -- Tema General (18), AcL -- LEKMA (110), EaT -- Tetteh Quarshie Memorial (13). Teaching hospitals: AcK -- Korle-Bu (699), AsK -- Komfo Anokye (7), NoT -- Tamale (102), CeT -- Cape Coast (6). Zonal public health reference laboratories: AcP -- National (0)\*, WsE -- Sekondi (152), AsP -- Kumasi (0)\*. Faith-based hospitals: EaN -- Holy Family, Nkawkaw (11), AsO -- St Patrick, Offinso (14), AsA -- Agogo Presbyterian (0)\*, BaB -- Holy Family, Brekum (19). Research laboratories: BaK -- Kintampo (2), UeW -- War Memorial (0)\*. Quasi Hospitals: Ac3 -- 37 Military Hospital (0)\*, CeU -- University, Cape Coast (3). () Data sets submitted. \*Laboratories that did not submit any data during the surveillance period.](idr-8-379Fig1){#f1-idr-8-379}

![Nationwide resistance profile of gram-negative isolates (**A**) and gram-positive isolates (**B**) from Ghana, June--November 2014.\
**Abbreviations:** BETA, beta-lactamase; ESBL, extended-spectrum beta-lactamase; AMP, ampicillin; PIP, piperacillin; AMC, augmentin; CXM, cefuroxime; CTX, cefotaxime; MEM, meropenem; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; ERY, erythromycin; NIT, nitrofurantoin; CHL, chloramphenicol; TCY, tetracycline; PNV, penicillin V; CLO, cloxacillin; FLC, flucloxacillin; OXA, oxacillin; FOX, cefoxitin; GEN, gentamicin.](idr-8-379Fig2){#f2-idr-8-379}

![Comparison of resistance profile of selected antimicrobial between southern, middle, and northern sectors of Ghana.\
**Note:** Differences observed in ciprofloxacin and penicillin is significant (*P*\<0.05).\
**Abbreviations:** CIP, ciprofloxacin; PEN, penicillin.](idr-8-379Fig3){#f3-idr-8-379}

###### 

Bacterial species isolated during 6-month surveillance of antimicrobial resistance, Ghana, June--November 2014

  Organism                              Number of isolates (%)   Inpatients   Outpatients   Source not indicated
  ------------------------------------- ------------------------ ------------ ------------- ----------------------
  *Acinetobacter* spp.                  25 (1.56)                9            11            5
  *Citrobacter koseri*                  17 (1.06)                1            15            1
  *Citrobacter* spp.                    146 (9.14)               43           87            16
  *Enterobacter* spp.                   149 (9.32)               42           83            24
  *Enterococcus* spp.                   3 (0.19)                 1            2             N/A
  *Escherichia coli*                    440 (27.53)              94           309           37
  *Klebsiella pneumoniae*               17 (1.06)                3            12            2
  *Klebsiella* spp.                     97 (6.07)                30           57            10
  *Moraxella* spp.                      3 (0.19)                 N/A          3             N/A
  *Morganella* spp.                     13 (0.81)                4            9             N/A
  *Proteus mirabilis*                   60 (3.75)                12           39            9
  *Proteus* spp.                        42 (2.63)                10           30            2
  *Providencia* spp.                    5 (0.31)                 3            1             1
  *Pseudomonas aeruginosa*              118 (7.38)               17           83            18
  *Pseudomonas* spp.                    147 (9.20)               46           90            11
  *Salmonella enterica* serovar Typhi   9 (0.56)                 3            5             1
  Nontyphoidal *Salmonella*             7 (0.44)                 5            1             1
  *Serratia* spp.                       15 (0.94)                12           2             1
  *Staphylococcus aureus*               183 (11.45)              57           111           15
  Coagulase-negative *Staphylococcus*   41 (2.57)                22           15            4
  *Stenotrophomonas maltophilia*        1 (0.06)                 N/A          1             N/A
  *Streptococcus pneumoniae*            2 (0.13)                 N/A          2             N/A
  Other *Streptococcus* spp.            35 (2.19)                18           13            4
  *Vibrio cholerae* O1 Ogawa            19 (1.19)                9            9             1
  Total                                 1,598 (100)              428          963           161

**Abbreviation:** N/A, not applicable.

###### 

Specimen types cultured at laboratories during 6-month nationwide surveillance of antimicrobial resistance, Ghana, June--November 2014

  Specimen type         Number of isolates   Southern                                    Middle   Northern                                                                                       
  --------------------- -------------------- ------------------------------------------- -------- ---------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Abdominal fluid       3                    1                                           N/A      N/A        N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Abscess               4                    1                                           1        N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   1     N/A   N/A   N/A   N/A   N/A
  Aspirate              33                   20                                          N/A      N/A        N/A   N/A   N/A   1     3     N/A   N/A   N/A   N/A   3     2     N/A   N/A   N/A   N/A
  Blood                 100                  [a](#tfn2-idr-8-379){ref-type="table-fn"}   16       N/A        N/A   N/A   1     N/A   14    7     1     1     N/A   45    1     N/A   N/A   13    1
  Burns                 1                    1                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Catheter              3                    3                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Cerebrospinal fluid   5                    3                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Cervix                2                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   2     N/A   N/A   N/A   N/A
  Cornea                3                    2                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Ear                   80                   24                                          10       N/A        1     N/A   N/A   10    7     N/A   1     N/A   N/A   N/A   16    1     2     N/A   1
  Eyes                  25                   18                                          1        1          N/A   N/A   N/A   N/A   1     N/A   N/A   2     N/A   N/A   1     N/A   N/A   N/A   N/A
  Gastric fluid         1                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Heart valve           1                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Joint                 1                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Nose                  2                    1                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Pleural fluid         3                    1                                           1        N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Prosthesis            1                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Pus                   8                    3                                           N/A      N/A        1     N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   2     N/A   N/A   N/A   N/A   N/A
  Rectal                2                    N/A                                         N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   2     N/A   N/A   N/A   N/A
  Sputum                69                   18                                          5        2          N/A   1     N/A   N/A   24    N/A   N/A   3     N/A   5     N/A   N/A   N/A   7     N/A
  Stool                 26                   1                                           2        N/A        N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A   5     17    N/A   N/A   N/A   N/A
  Swab                  5                    4                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Throat                2                    1                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   1     N/A   N/A   N/A   N/A   N/A
  Urethra               26                   N/A                                         3        N/A        2     N/A   N/A   5     2     N/A   N/A   N/A   N/A   11    N/A   N/A   N/A   1     N/A
  Urine                 617                  293                                         40       9          2     1     N/A   23    29    N/A   4     N/A   N/A   66    58    2     4     63    3
  Vagina                110                  1                                           6        2          4     1     2     5     34    N/A   2     N/A   N/A   15    25    N/A   1     9     2
  Wound                 415                  187                                         19       3          7     3     N/A   7     33    N/A   5     10    2     40    18    8     3     7     3
  Wound, surgical       4                    4                                           N/A      N/A        N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
  Not indicated         46                   26                                          4        8          1     N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A   4     N/A   N/A   N/A   N/A   N/A
  Total                 1,598                613                                         108      25         18    6     3     53    150   7     14    18    2     199   142   11    10    100   10

**Notes:**

Korle-Bu Teaching Hospital was not performing blood culture during the surveillance period. Southern sector: AcT -- Tema General Hospital; AcK -- Korle-Bu Teaching Hospital; AcL -- LEKMA Hospital; AcP -- National Public Health Reference Laboratory; AcR -- Ridge Hospital; Ac3 -- 37 Military Hospital; CeT -- Cape Coast Teaching Hospital; CeU -- University Hospital, Cape Coast; VoV -- Volta Regional Hospital; WsE -- Public Health Laboratory, Sekondi. Middle sector: EaT -- Tetteh Quarshie Memorial Hospital; EaK -- Eastern Regional Hospital, Koforidua; EaN -- Holy Family Hospital, Nkawkaw; AsK -- Komfo Anokye Teaching Hospital; AsO -- St Patrick's Hospital, Offinso; AsA -- Agogo Presbyterian Hospital; AsP -- Public Health Laboratory, Kumasi; BaS -- Brong Ahafo Regional Hospital, Sunyani; BaB -- Holy Family Hospital, Berekum; BaK -- Kintampo Health Research Centre. Northern sector: UeB -- Upper East Regional Hospital, Bolgatanga; UeW -- War Memorial Hospital, Navorongo; NoT -- Tamale Teaching Hospital; UwR -- Upper West Regional Hospital.

**Abbreviation:** N/A, not applicable.

###### 

Minimum inhibitory concentration of randomly selected isolates to some antimicrobial agents

  Organism/antimicrobial agent   n    MIC range, μg/mL   MIC 50   MIC 90
  ------------------------------ ---- ------------------ -------- --------
  *Escherichia coli*                                              
   Ciprofloxacin                 23   0.019--256         \>256    \>256
   Ceftriaxone                   9    0.015--256         \>256    \>256
  *Pseudomonas* spp.                                              
   Ciprofloxacin                 17   0.012--256         \>256    \>256
   Ceftriaxone                   8    0.38--256          4        \>256
   Amikacin                      17   0.75--128          3        48
  *Klebsiella* spp.                                               
   Ciprofloxacin                 7    0.016--256         2        \>256
  *Citrobacter* spp.                                              
   Ciprofloxacin                 8    0--256             \>256    \>256
  *Enterobacter* spp.                                             
   Ciprofloxacin                 7    \>256              \>256    \>256

**Abbreviations:** n, number; MIC~50~, minimum inhibitory concentration at 50%; MIC~90~, minimum inhibitory concentration at 90%.
